[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:mantle-cell-lymphoma:t-11-14":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Mantle Cell Lymphoma","t(11;14)",4,[8,16,23,29],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06084936","A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed\u002FRefractory Mantle Cell Lymphoma",[12],"Phase 3","RECRUITING","2026-08-26T02:18:51.009190Z","2026-05-05T02:43:28.290108Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05910801","Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",[20],"Phase 2","2026-08-26T02:15:23.202838Z","2026-05-05T02:43:27.931684Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07257055","Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study",[20],"2026-08-26T02:18:12.612955Z","2026-05-05T02:43:27.813302Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT04792489","DALY II USA\u002F MB-CART2019.1 for DLBCL",[20],"2026-08-26T02:16:01.910993Z","2026-07-19T19:36:05.118465Z"]